These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 39475359)

  • 1. Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.
    Fléchon A; Morales-Barrera R; Powles T; Alva A; Özgüroğlu M; Csöszi T; Loriot Y; Rodriguez-Vida A; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Gunduz S; Mamtani R; Yu EY; Montesa Pino A; Anido U; Sendur MAN; Gravis G; Révész J; Kostorov V; Huillard O; Ma J; Rajasagi M; Vajdi A; Lunceford J; Cristescu R; Imai K; Homet Moreno B; Matsubara N
    Clin Cancer Res; 2024 Dec; 30(23):5353-5364. PubMed ID: 39475359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Efficacy of Avelumab Maintenance Therapy Versus Continued Chemotherapy Followed by Pembrolizumab in Metastatic Urothelial Carcinoma With No Progression After 4 Cycles of Chemotherapy: A Retrospective Study Using Propensity Score Matching.
    Kobayashi K; Matsumoto H; Sakano S; Yamamoto M; Tsuchida M; Tei Y; Nagao K; Oba K; Kitahara S; Yano S; Yoshihiro S; Yamamoto Y; Ohmi C; Komatsu H; Misumi T; Akao J; Shiraishi K
    Clin Genitourin Cancer; 2024 Dec; 22(6):102212. PubMed ID: 39270620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis.
    Yang Y; Chen W; Dong L; Duan L; Gao P
    Clin Transl Oncol; 2024 Oct; 26(10):2488-2502. PubMed ID: 38625495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.
    Rha SY; Oh DY; Yañez P; Bai Y; Ryu MH; Lee J; Rivera F; Alves GV; Garrido M; Shiu KK; Fernández MG; Li J; Lowery MA; Çil T; Cruz FM; Qin S; Luo S; Pan H; Wainberg ZA; Yin L; Bordia S; Bhagia P; Wyrwicz LS;
    Lancet Oncol; 2023 Nov; 24(11):1181-1195. PubMed ID: 37875143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line pembrolizumab with or without chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up of the Japanese population of KEYNOTE‑048.
    Oridate N; Takahashi S; Tanaka K; Shimizu Y; Fujimoto Y; Matsumoto K; Yokota T; Yamazaki T; Takahashi M; Ueda T; Hanai N; Yamaguchi H; Hara H; Yoshizaki T; Yasumatsu R; Nakayama M; Shiga K; Fujii T; Mitsugi K; Takahashi K; Nohata N; Gumuscu B; Lerman N; Tahara M
    Int J Clin Oncol; 2024 Dec; 29(12):1825-1839. PubMed ID: 39382718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab alone or combined with chemotherapy versus chemotherapy for the treatment of metastatic cancer: A meta-analysis of randomized clinical trials.
    Yue Y; Wang Q; Wei M; Ding F; Li J; Zheng B
    Medicine (Baltimore); 2024 Dec; 103(50):e40826. PubMed ID: 39686474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Impact of Bone Metastasis in Patients With Metastatic Urothelial Carcinoma Treated With Durvalumab With or Without Tremelimumab in the DANUBE Study.
    Stecca C; Abdeljalil O; Sridhar SS
    Clin Genitourin Cancer; 2024 Dec; 22(6):102215. PubMed ID: 39353213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Appearance of New Lesions Associate With Poor Prognosis in Pembrolizumab-Treated Urothelial Carcinoma.
    Hara T; Teishima J; Okamura Y; Suzuki K; Bando Y; Terakawa T; Chiba K; Hyodo Y; Nakano Y; Miyake H
    Clin Genitourin Cancer; 2024 Dec; 22(6):102236. PubMed ID: 39471702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin- or Carboplatin-Based Chemotherapy Plus Pembrolizumab in Advanced Urothelial Cancer: Exploratory Analysis From the Phase 3 KEYNOTE-361 Study.
    Powles T; Csőszi T; Loriot Y; Matsubara N; Geczi L; Cheng SY; Fradet Y; Alva A; Oudard S; Vulsteke C; Morales-Barrera R; Fléchon A; Gunduz S; Liu CC; Moreno BH; Bavle A; Özgüroğlu M
    Clin Genitourin Cancer; 2024 Nov; 23(1):102261. PubMed ID: 39642775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial.
    Tewari KS; Colombo N; Monk BJ; Dubot C; Cáceres MV; Hasegawa K; Shapira-Frommer R; Salman P; Yañez E; Gümüs M; Olivera Hurtado de Mendoza M; Samouëlian V; Castonguay V; Arkhipov A; Tekin C; Li K; Toker S; Keefe SM; Lorusso D
    JAMA Oncol; 2024 Feb; 10(2):185-192. PubMed ID: 38095881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China.
    Li S; Shi Y; Dong H; Guo H; Xie Y; Sun Z; Zhang X; Kim E; Zhang J; Li Y; Xu C; Kadeerbai H; Lee S; Gorla S; Guo J; Sheng X
    Cancer Med; 2024 Nov; 13(21):e70368. PubMed ID: 39530574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A prospective phase Ⅱ clinical trial of toripalimab combined with platinum-based concurrent chemoradiotherapy and consolidation chemotherapy in patients with locally advanced cervical cancer].
    Chen J; Shi JM; Cao YJ; Li C; Li JY; Yuan ZY
    Zhonghua Yi Xue Za Zhi; 2024 Dec; 104(48):4402-4408. PubMed ID: 39690535
    [No Abstract]   [Full Text] [Related]  

  • 13. Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor.
    Bakaloudi DR; Talukder R; Makrakis D; Diamantopoulos L; Enright T; Leary JB; Patgunarajah U; Thomas VM; Swami U; Agarwal N; Jindal T; Koshkin VS; Brown JR; Barata P; Murgić J; Miletić M; Johnson J; Zakharia Y; Hui G; Drakaki A; Duran I; Buznego LA; Barrera RM; Castañeda DM; Rey-Cárdenas M; Castellano D; Nguyen CB; Park JJ; Alva A; McKay RR; Stewart TF; Epstein IB; Bellmunt J; Wright JL; Gupta S; Grivas P; Khaki AR
    Clin Genitourin Cancer; 2024 Dec; 22(6):102198. PubMed ID: 39241315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With
    Sweis RF; Gajate P; Morales-Barrera R; Lee JL; Necchi A; de Braud F; Penel N; Grünwald V; Maruzzo M; Meran J; Ishida TC; Bao W; Zhou Y; Ellinghaus P; Rosenberg JE
    JAMA Oncol; 2024 Nov; 10(11):1565-1570. PubMed ID: 39298147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis.
    Cirillo A; Marinelli D; Romeo U; Messineo D; De Felice F; De Vincentiis M; Valentini V; Mezi S; Valentini F; Vivona L; Chiavassa A; Cerbelli B; Santini D; Bossi P; Polimeni A; Marchetti P; Botticelli A
    BMC Cancer; 2024 Apr; 24(1):430. PubMed ID: 38589857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy.
    Kawachi H; Yamada T; Tamiya M; Negi Y; Kijima T; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Katayama Y; Nishioka N; Morimoto K; Iwasaku M; Tokuda S; Shimose T; Takayama K
    Oncoimmunology; 2025 Dec; 14(1):2442116. PubMed ID: 39681395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarker Analyses Investigating Disease Biology and Associations with Outcomes in the JAVELIN Merkel 200 Trial of Avelumab in Metastatic Merkel Cell Carcinoma.
    D'Angelo SP; Lebbé C; Nghiem P; Brohl AS; Mrowiec T; Leslie T; Georges S; Güzel G; Shah P
    Clin Cancer Res; 2024 Oct; 30(19):4352-4362. PubMed ID: 39047170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
    Llovet JM; Kudo M; Merle P; Meyer T; Qin S; Ikeda M; Xu R; Edeline J; Ryoo BY; Ren Z; Masi G; Kwiatkowski M; Lim HY; Kim JH; Breder V; Kumada H; Cheng AL; Galle PR; Kaneko S; Wang A; Mody K; Dutcus C; Dubrovsky L; Siegel AB; Finn RS;
    Lancet Oncol; 2023 Dec; 24(12):1399-1410. PubMed ID: 38039993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort.
    Tachibana Y; Morimoto K; Yamada T; Kawachi H; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Katayama Y; Nishioka N; Iwasaku M; Tokuda S; Kijima T; Takayama K
    Invest New Drugs; 2024 Oct; 42(5):538-546. PubMed ID: 39168900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 thresholds predict efficacy of immune checkpoint inhibition in first-line treatment of advanced gastroesophageal adenocarcinoma. A systematic review and meta-analysis of seven phase III randomized trials.
    Formica V; Morelli C; Fornaro L; Riondino S; Rofei M; Fontana E; Smyth EC; Roselli M; Arkenau HT
    ESMO Open; 2024 Nov; 9(11):103967. PubMed ID: 39541621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.